Fresenius Medical Care Corporation (FMS) Raised to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Fresenius Medical Care Corporation (NYSE:FMS) from a sell rating to a hold rating in a research note published on Monday morning.

According to Zacks, “Fresenius Medical Care has had a disappointing run on the bourse on a year-to-date basis. The company  ended the second quarter on a mixed note wherein adjusted earnings missed the Zacks Consensus Estimate, while revenues beat the same. Fresenius Medical Care reiterated its full-year guidance. We believe this is in tune with the company’s long-term objective or the ‘Growth Strategy 2020’, wherein it aims to drive revenues to $28 billion by 2020, corresponding to an average annual growth rate of 10%. A wide range of dialysis products, initiatives to attain market traction, solid international foothold, strategic acquisitions and divestments are major catalysts. Fresenius Medical Care has signed an agreement to acquire NxStage Medical for $2 billion. However, a tough regulatory environment, difficulties in boosting the profit margin in foreign legal paradigms and competition in the niche markets are major headwinds.”

FMS has been the subject of a number of other reports. UBS AG restated a sell rating on shares of Fresenius Medical Care Corporation in a research report on Tuesday, July 4th. Nord/LB restated a buy rating on shares of Fresenius Medical Care Corporation in a research report on Wednesday, June 28th. BidaskClub cut Fresenius Medical Care Corporation from a strong-buy rating to a buy rating in a research report on Monday, July 24th. Royal Bank Of Canada restated a neutral rating and issued a price objective on shares of Fresenius Medical Care Corporation in a research report on Tuesday, August 8th. Finally, DZ Bank AG restated a buy rating on shares of Fresenius Medical Care Corporation in a research report on Monday, August 7th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company’s stock. Fresenius Medical Care Corporation presently has an average rating of Hold and a consensus price target of $48.67.

Shares of Fresenius Medical Care Corporation (NYSE FMS) opened at 48.26 on Monday. Fresenius Medical Care Corporation has a one year low of $38.05 and a one year high of $50.22. The stock has a market capitalization of $29.62 billion, a price-to-earnings ratio of 20.71 and a beta of 0.48. The firm’s 50-day moving average is $48.17 and its 200-day moving average is $46.76.

Fresenius Medical Care Corporation (NYSE:FMS) last posted its quarterly earnings data on Tuesday, August 1st. The company reported $0.48 EPS for the quarter, missing the Zacks’ consensus estimate of $0.53 by ($0.05). The business had revenue of $4.47 billion during the quarter, compared to analysts’ expectations of $5.20 billion. Fresenius Medical Care Corporation had a net margin of 7.06% and a return on equity of 11.57%. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.96 earnings per share. Equities research analysts forecast that Fresenius Medical Care Corporation will post $2.34 EPS for the current year.

WARNING: This article was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.com-unik.info/2017/10/12/fresenius-medical-care-corporation-fms-raised-to-hold-at-zacks-investment-research.html.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Level Four Advisory Services LLC increased its position in shares of Fresenius Medical Care Corporation by 0.5% during the first quarter. Level Four Advisory Services LLC now owns 11,434 shares of the company’s stock worth $478,000 after purchasing an additional 58 shares in the last quarter. UBS Asset Management Americas Inc. increased its position in shares of Fresenius Medical Care Corporation by 3.6% during the second quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock worth $114,000 after purchasing an additional 81 shares in the last quarter. Greenleaf Trust increased its position in shares of Fresenius Medical Care Corporation by 2.6% during the second quarter. Greenleaf Trust now owns 4,992 shares of the company’s stock worth $241,000 after purchasing an additional 126 shares in the last quarter. Sawtooth Solutions LLC increased its position in shares of Fresenius Medical Care Corporation by 2.9% during the second quarter. Sawtooth Solutions LLC now owns 4,887 shares of the company’s stock worth $236,000 after purchasing an additional 137 shares in the last quarter. Finally, Wrapmanager Inc. increased its position in shares of Fresenius Medical Care Corporation by 2.4% during the second quarter. Wrapmanager Inc. now owns 7,392 shares of the company’s stock worth $357,000 after purchasing an additional 170 shares in the last quarter. Hedge funds and other institutional investors own 2.61% of the company’s stock.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Get a free copy of the Zacks research report on Fresenius Medical Care Corporation (FMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Fresenius Medical Care Corporation (NYSE:FMS)

What are top analysts saying about Fresenius Medical Care Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fresenius Medical Care Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit